… Several population pharmacokinetic (PopPK) models for meropenem dosing in ICU …
meropenem concentrations in an independent validation dataset when meropenem is infused …

… to develop a meropenem population pharmacokinetic model using patient … meropenem
0.5, 1, or 2 g over 0.5- or 3-hour infusion every 8 hours. Meropenem population pharmacokinetic …

… In the present study, we found that continuous iv infusions of meropenem at doses of 6 g/day
seem to be more effective than standard regimens (1–3 g twice or thrice per day as 3-h iv …

… now adds a population pharmacokinetic model of continuously infused meropenem in a
heterogeneous (with respect to demographics and disease severity) population of critically ill …

… Standard 0.5-hour meropenem infusions did not provide for appropriate pharmacodynamic
exposures of 40% free time > minimum inhibitory concentration (40% fT > MIC) for Gram-…

… in critically ill children, reinforcing the concept of increased clearance and highlighting the
benefit and safety of continuous infusion and the usefulness of clinical PK and therapeutic …

… Therefore, the present work aimed to develop and externally validate a population PK
model for continuous-infusion meropenem considering routinely available markers of renal …

… the population pharmacokinetics, tolerability and treatment burden of prolonged-infusion
meropenem … Herein, we describe the population pharmacokinetics, tolerability and feasibility of …

… , we assessed the population pharmacokinetics of meropenem in patients … meropenem
regimens which may be considered for optimal treatment of KPC-Kp infections due to meropenem…

… Simulations showed that in patients with increased eCL Cr , dose increment or continuous
infusion may be needed to obtain therapeutic meropenem concentrations. In conclusion, our …